Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice - PubMed
- ️Tue Jan 01 2008
Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice
Shuiping Tu et al. Cancer Cell. 2008.
Erratum in
- Cancer Cell. 2008 Dec 9;14(6):494
- Cancer Cell. 2011 Jan 18;19(1):154
Abstract
Polymorphisms of interleukin-1beta (IL-1beta) are associated with an increased risk of solid malignancies. Here, we show that stomach-specific expression of human IL-1beta in transgenic mice leads to spontaneous gastric inflammation and cancer that correlate with early recruitment of myeloid-derived suppressor cells (MDSCs) to the stomach. IL-1beta activates MDSCs in vitro and in vivo through an IL-1RI/NF-kappaB pathway. IL-1beta transgenic mice deficient in T and B lymphocytes develop gastric dysplasia accompanied by a marked increase in MDSCs in the stomach. Antagonism of IL-1 receptor signaling inhibits the development of gastric preneoplasia and suppresses MDSC mobilization. These results demonstrate that pathologic elevation of a single proinflammatory cytokine may be sufficient to induce neoplasia and provide a direct link between IL-1beta, MDSCs, and carcinogenesis.
Figures

(A) The construct pBS/HKATPase/ß globin/IL-1β, which contains the mouse H+/K+-ATPase ß subunit gene and secreted form of hIL-1β cDNA, was microinjected into fertilized mouse oocytes. (B) Expression of hIL-1β in the stomachs of 4 and 12 month old IL-1β transgenic mice and control mice was determined using a human-specific IL-1β ELISA kit. Data are the mean ± SD of 10 mice. (C) Expression of human (transgenic) and mouse (endogenous) IL-1β mRNA in stomach as assessed by RT-PCR. (D) IL-1β transgenic mice develop gastric hyperplasia (upper lane) and gastritis (H&E staining, lower lane). (E) Male Line 19 IL-1β transgenic mice develop stomach cancer. (F) Activation and relocalization of β-catenin in gastric cancer of IL-1β transgenic mice. The stomach sections were stained with an anti-β-catenin antibody. Arrows show nuclear β-catenin+ cells (brown).

(A) Stomach sections from Line 19 IL-1β transgenic and control mice infected with H. felis for 5 months were stained with H&E. (B) Pathological scores from the stomach of above mice were graded according to the diagnostic criterion described in Methods. The data represent the mean ± SD of 16 mice (#p < 0.05, vs WT mice; *p < 0.01, vs uninfected WT mice). (C) Expression of mouse TNF-α and IL-6 in stomach tissue from mice was determined by ELISA. The data represent the mean ± SD of 6 mice (#p < 0.05, vs WT mice; *p < 0.01, vs uninfected WT mice). (D) IL-1β transgenic mice infected with H. felis for 12 months developed dysplasia and carcinoma with activation of β-catenin. The sections from intramucosal/invasive gastric cancer were stained with anti-β-catenin and anti-c-Myc antibodies. Green arrows indicate invasive gastric cancer and pink arrows show nuclear β-catenin- or c-Myc-positive cells (brown), respectively. (E) Gastric inflammation and pathology scores were graded in Line 19 IL-1β transgenic and control mice infected with H. felis for 12 months. The data represent the mean ± SD of 10 animals (#p < 0.05, vs control mice; *p < 0.01, vs uninfected WT mice).

The frequencies of lymphoid and myeloid cells in peripheral blood (A), spleen (B) and stomach (C) from 2 month old IL-1β mice and age-matched WT mice were measured by FACS. The data are the mean ± SD of 6 mice (#p < 0.05, p < 0.01, vs WT mice). (D) Representative FACS blots for detecting lymphoid and myeloid cells in the stomach from WT and Line 19 IL-1β mice. (E) Expression of mouse TNF-α, IL-6 and SDF-1α in the gastric tissue from 2 month old mice was determined by ELISA. The data represent the mean ± SD of 6 animals (*p < 0.01, vs WT mice). (F-G) The kinetics of MDSCs was determined by FACS in peripheral blood (F) and stomach (G) from IL-1β mice and WT mice at different time points. The data represent the mean ± SD of 6 animals (#p < 0.05; *p < 0.01, vs WT mice).

(A) IL-1β upregulates EGFP mRNA expression by activates NF-κB in MDSCs. EGFP+ and EGFP- MDSCs from NF-κBEGFP mice were treated with IL-1β in absence or presence of 50 ng/ml IL-1RA or 1 μM MG132 for 3 hours. mRNA expression was determined by real time-PCR. The data are normalized to untreated EGFP- MDSCs and represent the mean ± SD of four independent experiments. (B) IL-1β upregulates expression of EGFP protein in MDSCs. EGFP+ and EGFP-MDSCs were treated with IL-1β for 24 hours. The EGFP fluorescence intensities were detected by FACS. (C) Expression of IL-1RI protein in MDSCs was determined by FACS using PE-IL-1RI antibody. (D) IL-1RI mRNA expression in MDSCs measured by RT-PCR. (E) Blocking IL-1β /NF-κB signal pathway inhibits IL-1β-stimulates secretion of IL-6 in MDSCs. EGFP+ MDSCs were treated with IL-1β in absence or presence of IL-1RA or MG132 for 36 hours. The level of IL-6 were measured by ELISA. The data represent the mean ± SD of four independent experiments (*p < 0.01, vs IL-1β treated group).

(A) NF-κB activation in the stomachs of IL-1β mice. Sections were stained a NF-κB p65 antibody. Arrows indicate p65+ cells. (B) Enhanced EGFP expression in IL-1β;NF-κBEGFP mice. Frozen gastric sections from 6 month old indicated mice were subjected to H&E staining and double staining with anti-EGFP (green) and E-cadherin (red) antibodies. The red staining indicates epithelial cells. Localization of EGFP+ cells is mostly confined to stromal region. (C) Increased frequencies of EGFP+ MDSCs in peripheral blood, spleen and stomach tissues in IL-1β;NF-κBEGFP mice as analyzed by FACS. The data represent the mean ± SD of 6 animals (*p < 0.05, vs NF-κBEGFP mice). (D) Increased expression of cytokines in stomach MDSCs in IL-1β;NF-κBEGFP mice. Stomach MDSCs sorted from 6 month old NF-κBEGFP and IL-1β;NF-κBEGFP mice were restimulated with PMA for 4 hours. mRNA expression was determined by real-time PCR. The data are normalized to MDSCs of NF-κBEGFP mice and represent the means ± SD of three independent experiments (*p < 0.01, vs NF-κBEGFP mice). (E) Blocking NF-κB activity by injecting i.p. Bay 11-7085 prevents EGFP expression in 3 month old IL-1β;NF-κBEGFP mice. Representative photos were taken from frozen gastric sections under fluorescence microscope. (F) Blocking NF-κB activity inhibits the development of gastritis. The pathological scores were graded in Bay 11-7085 or DMSO-treated IL-1β;NF-κBEGFP mice (*p < 0.05, vs DMSO treated mice, n = 8).

(A) IL-1β;Rag2-/- mice develop spontaneous gastritis and dysplasia (H&E staining). (B) The pathological scores were graded in old Rag2-/-, IL-1β;Rag2-/- and IL-1β;Rag2+/+ mice (>12 months). The data represent the mean ± SD of 10 animals (*p <0.01, vs Rag2-/- mice). (C-D) Increased the number of myeloid cells in the stomach of 6 month old IL-1 β;Rag2-/- mice. Representative FACS blots (C) and the data shown are the mean ± SD of cell number per stomach derived from 6 animals (D). (E) IL-1RA treatment inhibits the mobilization and recruitment of MDSCs in IL-1β;Rag2-/- mice. Three month old IL-1β;Rag2-/- mice were treated with IL-1RA for 6 weeks. Single nucleated cells isolated were stained with APC-CD11b and PerCP-Gr-1 antibodies and analyzed by FACS. (F) IL-1RA treatment inhibits the development of gastritis in IL-1β;Rag2-/- mice. The pathological scores were graded in above indicated mice The data represent the mean ± SD of 6 animals (*p < 0.05, vs untreated mice).

(A) IL-1RA treatment inhibits the mobilization of MDSCs. Single nucleated cells in peripheral blood were isolated from Line 19 IL-1β transgenic and control mice infected with H. felis for 5 months with or without preventive administration of IL-1RA. Cells were stained with fluorescence-labeled CD11b and Gr-1 antibodies and analyzed by FACS (*p < 0.05, vs untreated mice, n = 6). (B) IL-1RA treatment inhibits the development of gastric inflammation and preneoplasia in H. felis-infected mice. Histopathological scores assessed in mice (*p < 0.05, vs untreated mice, n = 6). Gastric expression of mouse TNF-α and IL-6 (C) and SDF-1α (D) in indicated mice were determined by ELISA. (E) IL-1RA treatment inhibits the development of gastric dysplasia in H. felis-infected IL-1β mice. Stomach sections were from Line 19 IL-1β transgenic and WT mice infected with H. felis for 12 months with or without IL-1RA treatment for 3 months. The histopathologic scores were graded (*p < 0.01, vs untreated mice, n = 10). Error bar in (A)-(E) indicate ± SD.
Similar articles
-
Okumura T, Ericksen RE, Takaishi S, Wang SS, Dubeykovskiy Z, Shibata W, Betz KS, Muthupalani S, Rogers AB, Fox JG, Rustgi AK, Wang TC. Okumura T, et al. Cancer Res. 2010 Nov 1;70(21):8435-45. doi: 10.1158/0008-5472.CAN-10-1506. Epub 2010 Oct 19. Cancer Res. 2010. PMID: 20959488 Free PMC article.
-
Ohtani M, Ge Z, García A, Rogers AB, Muthupalani S, Taylor NS, Xu S, Watanabe K, Feng Y, Marini RP, Whary MT, Wang TC, Fox JG. Ohtani M, et al. Carcinogenesis. 2011 Aug;32(8):1244-50. doi: 10.1093/carcin/bgr072. Epub 2011 May 11. Carcinogenesis. 2011. PMID: 21565825 Free PMC article.
-
Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD, Müller A. Hitzler I, et al. J Immunol. 2012 Apr 15;188(8):3594-602. doi: 10.4049/jimmunol.1103212. Epub 2012 Mar 7. J Immunol. 2012. PMID: 22403439
-
Khawar MB, Abbasi MH, Sheikh N. Khawar MB, et al. Mediators Inflamm. 2016;2016:8413768. doi: 10.1155/2016/8413768. Epub 2016 Apr 6. Mediators Inflamm. 2016. PMID: 27143819 Free PMC article. Review.
-
[Transgenic mouse model for imaging of inflammation in vivo].
Iwawaki T. Iwawaki T. Seikagaku. 2016 Apr;88(2):225-8. Seikagaku. 2016. PMID: 27192876 Review. Japanese. No abstract available.
Cited by
-
Chung Nien Chin S, O'Connor L, Scurr M, Busada JT, Graham AN, Alipour Talesh G, Tran CP, Sarkar S, Minamoto T, Giraud AS, Cidlowski JA, Sutton P, Menheniott TR. Chung Nien Chin S, et al. Am J Physiol Gastrointest Liver Physiol. 2020 Aug 1;319(2):G175-G188. doi: 10.1152/ajpgi.00019.2020. Epub 2020 Jun 15. Am J Physiol Gastrointest Liver Physiol. 2020. PMID: 32538140 Free PMC article.
-
Unique Versus Redundant Functions of IL-1α and IL-1β in the Tumor Microenvironment.
Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y, Rider P, Idan Cohen, Romzova M, Kaplanov I, Apte RN. Voronov E, et al. Front Immunol. 2013 Jul 8;4:177. doi: 10.3389/fimmu.2013.00177. eCollection 2013. Front Immunol. 2013. PMID: 23847618 Free PMC article.
-
Role of innate immunity in Helicobacter pylori-induced gastric malignancy.
Peek RM Jr, Fiske C, Wilson KT. Peek RM Jr, et al. Physiol Rev. 2010 Jul;90(3):831-58. doi: 10.1152/physrev.00039.2009. Physiol Rev. 2010. PMID: 20664074 Free PMC article. Review.
-
Cancer and inflammation: promise for biologic therapy.
Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Demaria S, et al. J Immunother. 2010 May;33(4):335-51. doi: 10.1097/CJI.0b013e3181d32e74. J Immunother. 2010. PMID: 20386472 Free PMC article. Review.
References
-
- Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678–689. - PubMed
-
- Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323–340. - PubMed
-
- Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25:409–416. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI051405/AI/NIAID NIH HHS/United States
- R01 CA093405/CA/NCI NIH HHS/United States
- R01CA093405/CA/NCI NIH HHS/United States
- U54 CA126513/CA/NCI NIH HHS/United States
- U54 CA126513-03/CA/NCI NIH HHS/United States
- R01CA120979/CA/NCI NIH HHS/United States
- R01 CA120979-03/CA/NCI NIH HHS/United States
- 1U54CA126513/CA/NCI NIH HHS/United States
- R01 AI051415/AI/NIAID NIH HHS/United States
- R01 CA093405-08/CA/NCI NIH HHS/United States
- R01 CA120979/CA/NCI NIH HHS/United States
- R01AI51415/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases